INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 220S220 trades$52.89M
  2. 02SPSaba Capital Management, L.P.66B / 18S · 11 late84 trades$24.31M
  3. 03SJSheena Jonathan0B / 57S57 trades$3.61M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 32S32 trades$5.48M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

69,544 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
19
AM
Angelidis-Smith MariaDirector
LMNDLemonade, Inc.
Grant or award
A$300K
5,390 sh
Mar 10, 2026Mar 12, 2026
Page 1128 of 1739
← PrevNext →
traded Mar 10, 2026
+2d
SEC Form 4

Evidence

19
NL
Nolf Aurelien Pierre LeonChief Financial Officer
NAVNNavan, Inc.
Grant or award
A—
779.0K sh
Mar 2, 2026Mar 12, 2026
traded Mar 2, 2026
+10dSEC Form 4

Evidence

19
NA
Nanduru AnilSenior Vice President
GGenpact LTD
Tax withholding
F$298K
7,663 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

18
LS
Leshinski ScottPresident
OSOneStream, Inc.
Open-market sale · 10b5-1 plan
SELL$176K
7,412 sh
Mar 11, 2026Mar 12, 2026
traded Mar 11, 2026
+1dSEC Form 4

Evidence

17
DF
De Bosschere FabriceChief Accounting Officer
MMIMarcus & Millichap, Inc.
Tax withholding
F$9,753
369 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
GC
Gallman CariEVP, General Counsel
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
5,201 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
CL
Caputo Richard L. Jr.SVP, Aerospace Systems
VVXV2X, Inc.
Option exercise
M—
1,269 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
BJ
Bennett Isham JayChief Human Resources Officer
SFDSMITHFIELD FOODS INC
Grant or award
A—
39.1K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
DF
De Bosschere FabriceChief Accounting Officer
MMIMarcus & Millichap, Inc.
Option exercise
M—
600 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
BP
Busque PhilippeSVP, GLOBAL SALES AND SERVICES
CTKBCytek Biosciences, Inc.
Option exercise
M—
2,049 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
PM
Pittenger MaureenEVP, Chief HR Officer
DPZDOMINOS PIZZA INC
Grant or award
A—
816 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
FC
Fitzgerald Lindsay ClintonChief Public Affairs Officer
GEVOGevo, Inc.
Open-market sale · 10b5-1 plan
SELL$50K
20.0K sh
Mar 12, 2026Mar 12, 2026
traded Mar 12, 2026
+0dSEC Form 4

Evidence

17
DF
De Bosschere FabriceChief Accounting Officer
MMIMarcus & Millichap, Inc.
Option exercise
M—
158 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
BE
Burkhart ErinSVP, Controllership
GILDGILEAD SCIENCES, INC.
Grant or award
A—
2,355 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
FC
Fargis Edward CEVP & General Counsel
PRVAPrivia Health Group, Inc.
Grant or award
A—
28.3K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
HW
Hobbs Mark WayneEVP
DKLDelek Logistics Partners, LP
Grant or award
A—
4,715 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
DM
Duncan Thomas MichaelSVP, Chief Accounting Officer
TNLTravel & Leisure Co.
Grant or award
A—
5,439 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
CJ
Checkovich Tennille J.Chief Legal Officer
SFDSMITHFIELD FOODS INC
Grant or award
A—
28.4K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
8,241 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
4,612 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Grant or award
A—
5,050 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
MP
Manchon PilarDirector
EBEventbrite, Inc.
Disposition to issuer
D—
30.5K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
LI
Layton Kathleen I.Chief Legal Officer
OPRTOportun Financial Corp
Grant or award
A—
70.4K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
1,246 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

17
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
1,050 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$55K
912 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$55K
913 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
2,264 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$51K
849 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
KD
Knight Lea DanielsEVP & Chief Financial Officer
IARTINTEGRA LIFESCIENCES HOLDINGS CORP
Tax withholding
F$78K
8,089 sh
Mar 11, 2026Mar 12, 2026
traded Mar 11, 2026
+1dSEC Form 4

Evidence

16
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$129K
2,146 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
PL
Pogosyan LianaChief Financial Officer
XOSXos, Inc.
Tax withholding
F$58K
28.1K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
GC
Gallman CariEVP, General Counsel
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$81K
1,354 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Tax withholding
F$90K
606 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

16
DM
Duncan Thomas MichaelSVP, Chief Accounting Officer
TNLTravel & Leisure Co.
Disposition to issuer
D$94K
1,326 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

15
VR
Vashisht RijuSenior Vice President
GGenpact LTD
Tax withholding
F$276K
7,080 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

14
SL
Schwartz LarissaSee Remarks
OKTAOkta, Inc.
Open-market sale · 10b5-1 plan
SELL$147K
1,836 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

13
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
838 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

13
SW
Short Bartie WendyEVP, Corporate Affairs
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
749 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence

13
BP
Busque PhilippeSVP, GLOBAL SALES AND SERVICES
CTKBCytek Biosciences, Inc.
Option exercise
M—
2,946 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC Form 4

Evidence